Skip to main content

Table 5 Prevalence estimates for England with and without linked secondary care data (2014 N = 1,802,468; 2019 N = 744,496)

From: UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records

  Individuals in England eligible for secondary care data linkage in 2014 N = 1,802,468 Individuals in England eligible for secondary care data linkage in 2019 N = 744,496
Standalone primary care data Both primary and secondary care data Standalone primary care data Both primary and secondary care data
n Point prevalence /100,000 (95% CI) N Point prevalence /100,000 (95% CI) n Point prevalence /100,000 (95% CI) n Point prevalence /100,000 (95% CI)
Underlying health conditions contributing to the at-risk population
 Chronic liver disease 4499 250 (242–257) 8104 450 (440–459) 2022 272 (260–284) 3941 529 (513–546)
 Chronic heart disease 87,217 4839 (4807–4870) 108,711 6031 (5997–6066) 29,399 3949 (3905–3993) 39,083 5250 (5199–5300)
 Chronic respiratory disease 53,358 2960 (2936–2985) 63,562 3526 (3500–3553) 21,345 2867 (2829–2905) 26,407 3547 (3505–3589)
 Current asthma (only) 125,548 6965 (6928–7003) 136,702 7584 (7546–7623) 48,009 6449 (6393–6505) 53,030 7123 (7065–7182)
 Chronic neurological disease 60,482 3356 (3329–3382) 69,932 3880 (3852–3908) 21,818 2931 (2892–2969) 26,284 3530 (3489–3573)
 Diabetes mellitus 110,144 6111 (6076–6146) 114,149 6333 (6297–6369) 48,461 6509 (6453–6566) 50,760 6818 (6761–6876)
 Organ transplant recipient 1470 82 (77–86) 1732 96 (92–101) 707 95 (88–102) 838 113 (105–120)
 Asplenia/sickle cell disease 2545 141 (136–147) 2878 160 (154–166) 1089 146 (138–155) 1346 181 (171–191)
 Other immunosuppression 14,134 784 (771–797) 32,537 1805 (1786–1825) 5035 676 (658–695) 7663 1029 (1006–1052)
 Chronic kidney disease 159,241 8835 (8793–8876) 159,379 8842 (8801–8884) 54,661 7342 (7283–7401) 54,774 7357 (7298–7417)
 Severe obesity (BMI ≥40 kg/m2) 36,668 2581 (2555–2607) 36,668 2581 (2555–2607) 16,706 2898 (2855–2942) 16,706 2898 (2855–2942)
At-risk populationa
 At-risk populationa 450,601 24,999 (24,936–25,062) 483,071 26,801 (26,736–26,865) 175,420 23,562 (23,466–23,659) 188,716 25,348 (25,249–25,447)
 among those aged < 70 years 276,158 17,756 (17,696–17,816) 303,528 19,516 (19,453–19,578) 112,168 17,286 (17,194–17,378) 123,038 18,961 (18,866–19,057)
 among those aged ≥70 years 174,443 70,579 (70,399–70,759) 179,543 72,643 (72,466–72,818) 63,252 66,157 (65,856–66,457) 65,678 68,694 (68,399–68,988)
 Multimorbidity 133,803 7423 (7385–7462) 155,802 8644 (8603–8685) 48,009 6449 (6393–6505) 56,827 7633 (7573–7693)
Cancer survivors
 Incident cancer in previous year 8343 463 (453–473) 10,680 593 (581–604) 2936 394 (380–409) 3806 511 (495–528)
 Incident cancer in previous 5 years 31,195 1731 (1712–1750) 36,815 2042 (2022–2063) 11,708 1573 (1544–1601) 13,854 1861 (1830–1892)
  1. 95% CI, 95% confidence interval.
  2. aThe at-risk population comprised individuals with: any history of chronic respiratory disease other than asthma, heart disease, kidney disease, neurological conditions such as multiple sclerosis, diabetes mellitus; or with current asthma, severe obesity, or immunosuppression; assessed at each index date.